Skip to main content
    R

    Rallybio Corp (RLYB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.43
    -0.30 (-1.88%)

    Market Cap: $88.03M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Rallybio Corp (RLYB) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Rallybio are Zura Bio Limited Class A Ordinary Shares (ZURA), TuHURA Biosciences (HURA) and Rani Therapeutics Holdings (RANI). By market cap, Rallybio ranks 7th of the 13 companies on this page; Upstream Bio (UPB) is the largest at $152.38M.

    Peer Comparison

    RLYB's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Rallybio (RLYB)$88.03MN/A203.1x6177.0%N/A0.0%0.00%
    Zura Bio Limited Class A Ordinary Shares (ZURA)$119.44MN/AN/A0.0%N/A0.0%0.00%
    TuHURA Biosciences Inc (HURA)$88.58MN/AN/A0.0%-81.8%0.0%0.00%
    Rani Therapeutics Holdings Inc (RANI)$60.78MN/A16.3x0.0%N/A893.0%0.00%
    Coherus BioSciences Inc (CHRS)$81.21MN/A1.5x-253.4%-144.8%23.4%0.00%
    Tiziana Life Sciences Ltd (TLSA)$72.53MN/AN/A0.0%N/A0.0%0.00%
    NRX Pharmaceuticals Inc (NRXP)$95.58MN/A23.8x0.0%N/A0.0%0.00%
    Corbus Pharmaceuticals Holding (CRBP)$69.86MN/A13.9x0.0%-106.7%-100.0%0.00%
    PDS Biotechnology Corp (PDSB)$107.07MN/AN/A0.0%-149.8%0.0%0.00%
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    Mereo BioPharma Group PLC ADR (MREO)$49.11MN/A61.3x0.0%-116.6%0.0%0.00%
    RenovoRx Inc (RNXT)$50.18MN/A16.6x0.0%N/A300.8%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    Peer median$84.89MN/A16.6x0.0%-116.6%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Rallybio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Zura Bio Limited Class A Ordinary Shares (ZURA)
    Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases.
    ZURA competitors
    TuHURA Biosciences Inc (HURA)
    TuHURA Biosciences Inc is a pioneering biotechnology firm committed to advancing immunotherapy solutions for cancer and autoimmune diseases.
    HURA competitors
    Rani Therapeutics Holdings Inc (RANI)
    Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology...
    RANI competitors
    Coherus BioSciences Inc (CHRS)
    Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States.
    CHRS competitors
    Tiziana Life Sciences Ltd (TLSA)
    Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat...
    NRX Pharmaceuticals Inc (NRXP)
    NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company...
    NRXP competitors
    Corbus Pharmaceuticals Holding (CRBP)
    Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target...
    CRBP competitors
    PDS Biotechnology Corp (PDSB)
    PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies.
    PDSB competitors
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
    NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy...
    NTHI competitors
    Mereo BioPharma Group PLC ADR (MREO)
    Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases...
    MREO competitors
    RenovoRx Inc (RNXT)
    RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.
    RNXT competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors

    Frequently Asked Questions About RLYB

    Who are Rallybio's main competitors?

    The companies most similar to Rallybio include Zura Bio Limited Class A Ordinary Shares (ZURA), TuHURA Biosciences (HURA), Rani Therapeutics Holdings (RANI), Coherus BioSciences (CHRS) and Tiziana Life Sciences (TLSA), listed from the closest match.

    Who is Rallybio's biggest competitor?

    Upstream Bio (UPB) is the largest of the similar companies at $152.38M; Zura Bio Limited Class A Ordinary Shares (ZURA) is the closest match by business profile, size, sector and industry.

    How does RLYB stock compare with its competitors?

    RLYB's P/S is 203.1x against a peer median of 16.6x; its net margin is 6177.0% against a peer median of 0.0%.

    Which of Rallybio's competitors pays a higher dividend?

    Rallybio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Rallybio bigger than its competitors?

    No. Rallybio is 7th by market cap among the 13 companies on this page; the largest is Upstream Bio (UPB) at $152.38M.